1-3 of 3
Victoria Richon, PhD
Close
Sort by
Journal Articles

Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells.

Angela Hatter, BS, Purva Bali, MS, Maria Balasis, BS, Warren Fiskus, PhD, Sandhya Boyapalle, PhD, Sandhya Kumaraswamy, PhD, Kathy Rocha, BS, Michael Pranpat, BS, Alison Hannah, MD, Eduardo Sotomayor, MD, PhD, Victoria Richon, PhD, Kapil Bhalla, MD
Journal: Blood
Blood (2005) 106 (11): 2418.
https://doi.org/10.1182/blood.V106.11.2418.2418
Published: 2005
Journal Articles

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

Guillermo Garcia-Manero, MD, Hui Yang, MD, PhD, Blanca Sanchez-Gonzalez, MD, Srdan Verstovsek, MD, Alessandra Ferrajoli, MD, Michael Keating, MD, Michael Andreeff, MD, Susan O’Brien, MD, Jorge Cortes, MD, William Wierda, MD, PhD, Stefan Faderl, MD, Charles Koller, MD, Jan Davis, RN, Gail Morris, RN, Jean-Pierre Issa, MD, Stanley R. Frankel, MD, Victoria Richon, PhD, Bernard Fine, PhD, Hagop Kantarjian, MD
Journal: Blood
Blood (2005) 106 (11): 2801.
https://doi.org/10.1182/blood.V106.11.2801.2801
Published: 2005
Journal Articles

Co-Treatment with a Novel Heat Shock Protein (hsp) 90 Inhibitor IPI504 and the Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Wild Type or Mutant Bcr-Abl-T315I or FLT-3-ITD-Containing Human Leukemia Cells.

Warren Fiskus, PhD, Purva Bali, MS, Michael Pranpat, MS, Maria Balasis, BS, Sandhya Kumaraswamy, PhD, Sandhya Boyapalle, PhD, Kathy Rocha, BS, Jeffery Tong, MD, Victoria Richon, PhD, Emmanuel Normant, PhD, Kapil Bhalla, MD
Journal: Blood
Blood (2005) 106 (11): 4461.
https://doi.org/10.1182/blood.V106.11.4461.4461
Published: 2005